Medical cannabis is gaining widespread acceptance due to increased awareness. Notably, several countries are looking into cannabis as an alternative for existing medicine. So, Tilray expects about 40–80 countries to legalize medical cannabis over the next two or three years. To learn more, read Tilray’s Stock Price Is Subdued Despite Global Opportunities.
Currently, there are studies related to medical cannabis to treat:
- nausea and vomiting—effects of chemotherapy in cancer patients
- chronic pain associated with traumatic spinal cord injuries, spina bifida, and osteoarthritis
- reducing muscle stiffness
- multiple sclerosis
- mental disorders
- Crohn’s disease and a variety of illnesses
Overall, there’s a widespread belief in the healthcare community that medical marijuana helps alleviate the above conditions. Notably, companies like Tilray (TLRY) and Canopy Growth (WEED) (CGC) already sell medical cannabis. They’re conducting clinical trials on the effectiveness of using cannabis for medical treatment.
Medical cannabis and blood pressure
While there’s a lot of optimism about cannabis use, there’s another side to the story. There’s a lack of research on the effectiveness of medical cannabis. As a result, there are concerns about using cannabis as an alternative to traditional drugs. A study found a modest link between cannabis use and an increase in systolic blood pressure in US adults. Overall, the study concluded that “With the legalization of cannabis, there a need for pre-clinical, clinical and prospective population-based research on the cardiovascular effects of cannabis use.”
Cannabis and heart disease
Dr. Andrew Pipe, a physician and researcher at Ottawa Heart Institute’s Division of Prevention and Rehabilitation, discussed how cannabis impacts the heart. He said, “When we consider marijuana and issues relating to the heart we really are steering into terra incognita.”
As a result, there’s certainly a significant need for formal medical cannabis research. The potential effects on human health require research. Recently, Harvard Health mentioned that the effects of cannabis on cardiovascular health “aren’t well studied.” According to Harvard Health, people who smoke cannabis have a higher heart attack risk.
Currently, the FDA has only started to scratch the surface regarding medical cannabis. According to the FDA, the information related to the effects of cannabis is “very limited.” As a result, there aren’t many CBD-based drugs approved by the FDA.
Overall, Harvard Health concluded that “it should be a red flag for anyone with a history of heart disease.” There are a lot of gaps that cannabis research needs to fill before medical cannabis gains mainstream acceptance. Aurora Cannabis (ACB), which is a medical company at heart, has a big task ahead. Likewise, other cannabis companies need to address the above-stated issues to gain a sizable market, especially the US CBD market. Read Why Is the US CBD Market So Attractive? to learn more.